• Pentixapharm received FDA clearance to begin the Phase III PANDA study of [68Ga]Ga-PentixaFor in primary aldosteronism; no trial results have been presented yet.
• The trial is designed to support use of a non-invasive PET/CT scan to localize aldosterone overproduction, potentially reducing reliance on invasive adrenal vein sampling.
• The company targets about 270 patients, with study start planned for the second half of the year.
• US launch is planned for 2030 if development stays on track.
• Management forecasts annual revenue potential above USD 1 billion several years post-approval, citing a large underdiagnosed hypertension-related market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.